LOS ANGELES, CA – Amazon’s latest series, “The Pradeeps of Pittsburgh,” is a comedy that is anchored in the immigrant ethos and highlights both the challenges and joys of families navigating a new ...

DALLAS, TX (IANS) – Actor Naveen Polishetty, who is known for his work in Telugu cinema, and rose to prominence with the sketches of the comedy collective ‘AIB’, has been injured as he met with a bike ...

Actors Naveen Polishetty and Meenakshi Chaudhary are celebrating the massive success of their film 'Anaganaga Oka Raju,' which has crossed Rs 100 crore worldwide. A spontaneous dance performance by ...

The Department of Justice is requiring Reddy Ice LLC to divest assets across five states to resolve antitrust concerns from its planned acquisition of an ice maker backed by private equity firm ...

Dr. Reddy's Laboratories (RDY) on Wednesday announced that India’s drug regulator, the Drugs Controller General of India, has issued marketing and manufacturing authorization for a generic version of ...

HYDERABAD, Jan 21 (Reuters) - Indian drugmaker Dr Reddy's (REDY.NS), opens new tab, which reported a smaller-than-expected fall in quarterly profit on Wednesday, said that it has received an approval ...

After a tough Rogue Mega Pokemon battle in the previous mission, it is now time for a quick little side story in the Pokemon Legends: Z-A Mega Dimension DLC. Here’s the walkthrough for checking out ...

Naveen Rao, the former head of AI at Databricks, has raised $475 million in seed capital at a $4.5 billion valuation for his new startup, Unconventional AI. The round was led by Andreessen Horowitz ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key ...

Naveen Kumar. Ph.D. is an Associate Professor in the Management Information Systems (MIS) division at the Price College of Business, University of Oklahoma, Norman, and has years of experience in ...

Dr. Reddy’s Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, ...